Thursday, November 21, 2024
11/21/2024
PI: Yi Zhang Graft-versus-host disease (GVHD), a cause of life-threatening complication in cancer patients following allogeneic hematopoietic cell transplantation, causes reconstitution of donor plasmacytoid dendritic cells (pDCs) to fail, as pDCs are critical for immune protection and tolerance. However, little is known about GVHD-associated pDC molecular defects and the precise effect of donor pDCs on GVHD in cancer. We used both murine and human systems to uncover the mechanisms by which GVHD induces donor pDC defects. GVHD depleted donor multipotent progenitors (MPPs) that sustain pDCs, leading to impaired pDC generation. MPP loss was associated with decreased numbers of MPP-producing hematopoietic stem cells (HSCs) and oxidative stress-induced death of remaining proliferating MPPs; this correlates with the common clinical observation of low blood counts in the setting of GVHD. In our models, alloreactive T cells produce GM-CSF to inhibit MPP expression of Tcf4, the transcription factor essential for pDC development, subverting MPP production of pDCs. GM-CSF did not affect the maturation of pDC precursors. Notably, enhanced recovery of donor pDCs upon adoptive transfer early after allogeneic HSC transplantation (allo-HSCT) repressed GVHD and restored de novo generation of donor pDCs in recipient mice. pDCs suppress the proliferation and expansion of activated T cells via a type-I IFN signaling-dependent mechanism. They also produce PD-L1 and LILRB4 to inhibit T cell production of IFN-. Thus, MPPs represent an effective target to bolster pDC reconstitution for GVHD prevention. In spite of these promising preliminary findings, the mechanisms by which MPPs produce pDCs and GVHD impairs MPPs after allo-HSCT in cancer patients as well as patients undergoing allo-HSCT for other diseases remain unknown. Our continuing studies suggested that Dot1l, which catalyzes H3K79 methylation, is crucial for pDC development. Dot1l appears to be critical for HSC and MPP differentiation into pDCs, PD-L1- and LILRB4-expressing pDCs (termed P/L+ pDCs) in particular. GVHD decreases Dot1l function in MPPs. Thus, impaired Dot1l activity may be the major contributor to pDC defects during GVHD. Successful harnessing of pDCs for GVHD prevention will rely on an understanding of how Dot1l regulates MPP generation, maintenance and pDC formation. We hypothesize that Dot1l promotes the generation and maintenance of MPPs and regulates pDC specification of MPPs. Alloreactive T cell responses can inhibit this Dot1l effect, inducing pDC defects and causing feed-forward GVHD exacerbation. Aim-1 will define the role of Dot1l in pDC reconstitution and the impact of GVHD on Dot1l action in HSPCs. Aim-2 will determine the molecular mechanisms through which pDCs repress alloreactive T cell responses. Aim-3 focuses on the impact of human pDCs on alloreactive T cell responses and assesses whether donor P/L+ pDCs in the allografts can be utilized to predict GVHD in cancer patients. Our proposal explores a heretofore unrecognized role of Dot1l in controlling pDC production and function. If successful, our work will open up new avenues to better understand pDC pathophysiology and translate pDC-based therapies to the clinic to help patients with hematologic malignancies and other blood diseases undergoing allo-HSCT.
HHS’ Tracking Accountability in Government Grants System (TAGGS) website provides access to detailed descriptions of grants, loans, aggregated direct payments and other types of financial assistance awarded by the HHS Operating Divisions (OPDIVs) and the Office of the Secretary Staff Divisions (STAFFDIVs).
